CD4 and cancer: Indeed, preclinical analysis has shown FGFR inhibitors to broaden the T-cell repertoire in cancer models through increased CD4+ and CD8+ T-cell infiltration; the same analysis also demonstrated immune checkpoint inhibitors to focus this pre-existing T-cell response through clonal expansion.39